Sandoz is arguing the Federal Circuit misinterpreted federal law when ruling that biosimilar makers must wait six months after an FDA approval to launch a product.
Source: Drug Industry Daily
Sandoz is arguing the Federal Circuit misinterpreted federal law when ruling that biosimilar makers must wait six months after an FDA approval to launch a product.
Source: Drug Industry Daily